$AMPH News

Amphastar Pharmaceuticals (NASDAQ:AMPH) Stands Out as a Quality Investing Candidate

Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript

Amphastar Pharmaceuticals (NASDAQ:AMPH) Beats Q2 Earnings Estimates, Shares Rise After Hours

Amphastar Pharma Q2 Adj. EPS $0.91 Beats $0.62 Estimate, Sales $183.903M Beat $182.055M Estimate

Amphastar Pharmaceuticals (NASDAQ:AMPH) Screens as a High-Quality Stock with Deep Value Appeal

Amphastar Pharmaceuticals Unit International Medication Systems Receives FDA Warning Letter Regarding Violations Of Current Good Manufacturing Practice At IMS's Drug Manufacturing Facility In California

B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow

Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty

Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference

Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19

Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today

The 5 Most Interesting Analyst Questions From Amphastar Pharmaceuticals’s Q1 Earnings Call

Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment

Amphastar Pharmaceuticals' (NASDAQ:AMPH) Conservative Accounting Might Explain Soft Earnings

Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19